School of Public Health students Cory Anderson, Delaine Anderson, Alexandria Kristensen-Cabrera, Emily McGuire, and Sarah Samorodnitsky have each been awarded the President’s Student Leadership & Service Award from the University of Minnesota.
The University research team — which included Division of Biostatistics researchers Joseph Koopmeiners, Thomas Murray, and Helen Voelker — found that the blood pressure medication did not protect the lungs of patients admitted with COVID-19, and had no effect on mortality.
The new program is designed to accommodate students from a wide variety of backgrounds and offers the opportunity to combine public health and data science into one degree.
Biostatistics Professor Wei Pan has been given the University’s highest recognition of health-related research — membership in the Academy for Excellence in Health Research.
Professor Joseph Koopmeiners explains how the typical three-phase clinical trial works and the ways researchers and the FDA are safely speeding up the development of COVID-19 vaccines.
A global clinical trial in hospitalized patients is looking for answers.
Professors Baolin Wu and Jim Pankow are leading a new study to identify the segments of human genetic code associated with the onset of diabetes.
Biostatistician and Assistant Professor Mark Fiecas is co-leading a study looking at the emergence of depression and suicide risk in thousands of adolescents and how it relates to the behavior of specific brain regions over time.
School of Public Health and Medical School researchers are conducting two new studies to see if losartan can protect the lungs of COVID-19 patients.
The study co-authored by Associate Professor Kyle Rudser revealed increased stiffness in the abdominal aorta in children exposed to secondhand smoke.
The study co-led by Professor John Connett revealed no beneficial effect of beta blockers on the overall risk of exacerbations and strong evidence that using the drug was associated with severe exacerbations requiring hospitalization.
The project is led by Professor Haitao Chu and will create tools to aid medical researchers and decision-makers in understanding the benefits and risks of different diagnostic or treatment options.